Abivax SA (NASDAQ:ABVX) shared additional clinical data on Monday for obefazimod at the United European Gastroenterology (UEG) Meeting.
These data, from the Phase 3 ABTECT 8-Week Induction Trials investigating obefazimod for moderate-to-severely active ulcerative colitis, highlight additional efficacy endpoint data at week eight for patients with and without prior advanced therapy inadequate response (AT-IR).
